Neumora Therapeutics, Inc. (NMRA)
NMRA moved a median of -0.29% 30 minutes after news, and -0.60% by the close. How NMRA actually reacts to news — the realized, point-in-time move the market made, measured across 901 labeled events over the last three years with zero look-ahead.
NMRA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 41% | 898 |
| 30-min | -0.29% | 41% | 900 |
| 60-min | -0.60% | 40% | 900 |
| to close | -0.60% | 39% | 899 |
| Middle 50% of NMRA reactions | -2.19% to +0.93% |
|---|---|
| Median reaction (30-min) | -0.29% |
| Measured reactions | 901 |
Half of all Neumora Therapeutics, Inc. news events land between -2.19% and +0.93% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How NMRA reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 11 | -0.90% | 36% | -0.37% |
| Analyst downgrades | 21 | +2.45% | 86% | +5.66% |
| Coverage initiations | 35 | -4.53% | 11% | -8.44% |
| Rating reiterations | 52 | +0.17% | 54% | -0.36% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how NMRA ranks against every other measured name →
That’s how NMRA usually reacts — get an email when it moves on news →Email me when NMRA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to NMRA's baseline. Nothing else.
Recent NMRA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 10-Q Neumora Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -3.43% | -5.33% | |
| Form 8-K Neumora Therapeutics, For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | -3.43% | -5.33% | |
| Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | -3.43% | -5.33% | |
| Form 8-K Neumora Therapeutics, For: Jul 27 | SEC filing · Form 8-K | SEC EDGAR | +1.32% | +9.93% | |
| Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026 | Press release | GlobeNewswire | +1.32% | +9.93% | |
| NMRA SHAREHOLDER INVESTIGATION: SueWallSt Investigates Neumora Therapeutics for Possible Securities Law Violations | Press release | PR Newswire | -4.77% | +4.79% | |
| Form 8-K Neumora Therapeutics, For: Jun 10 | SEC filing · Form 8-K | SEC EDGAR | +2.32% | -1.69% | |
| Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update | Press release | GlobeNewswire | +2.32% | -1.69% | |
| Form 8-K Neumora Therapeutics, For: May 27 | SEC filing · Form 8-K | SEC EDGAR | -1.35% | -1.62% | |
| Neumora Therapeutics to Participate in 2026 RBC Capital Markets Global Healthcare Conference | Press release | GlobeNewswire | -0.69% | -6.32% | |
| Form 10-Q Neumora Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.52% | -7.11% | |
| Form 8-K Neumora Therapeutics, For: May 07 | SEC filing · Form 8-K | SEC EDGAR | -0.43% | -16.74% | |
| Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | -0.43% | -16.74% | |
| Form DEF 14A Neumora Therapeutics, For: May 27 | SEC filing · Form DEF | SEC EDGAR | -0.47% | +3.30% | |
| Form DEFA14A Neumora Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | -0.47% | +3.30% | |
| Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference | Press release | GlobeNewswire | -0.75% | +6.00% | |
| Form 10-K Neumora Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -6.52% | -10.23% | |
| Form 8-K Neumora Therapeutics, For: Mar 30 | SEC filing · Form 8-K | SEC EDGAR | -6.52% | -10.23% | |
| Form S-8 Neumora Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | -6.52% | -10.23% | |
| Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | -6.52% | -10.23% | |
| Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026 | Press release | GlobeNewswire | +2.30% | -5.59% | |
| Form 8-K Neumora Therapeutics, For: Feb 11 | SEC filing · Form 8-K | SEC EDGAR | -1.13% | +2.39% | |
| Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 | Press release | GlobeNewswire | +0.00% | -0.49% | |
| Form 8-K Neumora Therapeutics, For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | -5.08% | -2.20% | |
| Form 8-K Neumora Therapeutics, For: Jan 05 | SEC filing · Form 8-K | SEC EDGAR | -3.53% | -11.14% | |
| Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer’s Disease Agitation | Press release | GlobeNewswire | -3.53% | -11.14% | |
| Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones | Press release | GlobeNewswire | -3.53% | -11.14% | |
| Form 8-K Neumora Therapeutics, For: Nov 17 | SEC filing · Form 8-K | SEC EDGAR | -2.15% | -7.30% | |
| Form 10-Q Neumora Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.63% | +2.40% | |
| Form 8-K Neumora Therapeutics, For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +7.50% | |
| Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | +0.00% | +7.50% | |
| Neumora Therapeutics to Participate in Upcoming Conferences in November | Press release | GlobeNewswire | +0.17% | -0.66% | |
| Form 8-K Neumora Therapeutics, For: Oct 27 | SEC filing · Form 8-K | SEC EDGAR | -3.67% | -0.37% | |
| Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model | Press release | GlobeNewswire | -3.67% | -0.37% | |
| Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898 | Press release | GlobeNewswire | -3.67% | -0.37% | |
| Neumora Therapeutics to Host Virtual R&D Day on October 27 | Press release | GlobeNewswire | +0.83% | -1.66% | |
| Neumora Therapeutics to Participate in Upcoming Conferences in September | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Form 10-Q Neumora Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.81% | -0.60% | |
| Form 8-K Neumora Therapeutics, For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +1.81% | -0.60% | |
| Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | +1.81% | -0.60% | |
| Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 | Press release | GlobeNewswire | -1.32% | -2.12% | |
| Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861 | Press release | GlobeNewswire | +4.44% | +13.33% | |
| Form 8-K Neumora Therapeutics, For: May 28 | SEC filing · Form 8-K | SEC EDGAR | +2.10% | +8.39% | |
| Form 8-K Neumora Therapeutics, For: May 14 | SEC filing · Form 8-K | SEC EDGAR | +0.07% | +3.06% | |
| Form DEFA14A Neumora Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +0.07% | +3.06% | |
| Form 10-Q Neumora Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +5.32% | -1.71% | |
| Form 8-K Neumora Therapeutics, For: May 12 | SEC filing · Form 8-K | SEC EDGAR | +5.32% | -1.71% | |
| Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | +5.32% | -1.71% | |
| Form DEF 14A Neumora Therapeutics, For: May 28 | SEC filing · Form DEF | SEC EDGAR | -0.59% | +2.20% | |
| Form DEFA14A Neumora Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | -0.59% | +2.20% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the NMRA section they belong to.
Where else NMRA is measured.
NMRA earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Neumora Therapeutics, Inc.'s median reaction calculated?
Every labeled NMRA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 901 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 41% of NMRA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does NMRA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.